ADMA Biologics logo
ADMA Biologics ADMA
$ 14.32 -4.66%

Annual report 2025
added 02-25-2026

report update icon

ADMA Biologics Cash Flow 2011-2026 | ADMA

Annual Cash Flow ADMA Biologics

2025 2024 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011

Operating Cash Flow

50.4 M 119 M 8.8 M -59.5 M -112 M -102 M -76.2 M -62.7 M -37.3 M -18.3 M -15.4 M -14.7 M -10.9 M -6.9 M -1.43 M

Depreciation & Amortization

8 M 7.7 M 7.6 M 6.4 M 4.8 M 3.2 M 2.4 M 2.6 M 1.5 M 400 K 470 K 248 K 211 K 182 K 220 K

Accounts Payables

22.5 M 20.2 M 15.7 M 13.2 M 12.4 M 11.1 M 9.17 M 5.9 M 5.92 M 2.56 M 2.09 M 1.78 M 2.71 M 1.06 M -

Accounts Receivables

158 M 50 M 27.4 M 15.5 M 28.6 M 13.2 M 3.47 M 1.39 M 3.88 M 1.02 M 924 K 384 K - 39.1 K -

Total Inventories

206 M 170 M 173 M 163 M 125 M 81.5 M 53.1 M 18.6 M 12.6 M 5.02 M 3.45 M 1.71 M 1.67 M 1.27 M -

All numbers in USD currency

Quarterly Cash Flow ADMA Biologics

2025-Q3 2025-Q2 2025-Q1 2024-Q4 2024-Q3 2024-Q2 2024-Q1 2023-Q4 2023-Q3 2023-Q2 2023-Q1 2022-Q4 2022-Q3 2022-Q2 2022-Q1 2021-Q4 2021-Q3 2021-Q2 2021-Q1 2020-Q4 2020-Q3 2020-Q2 2020-Q1 2019-Q4 2019-Q3 2019-Q2 2019-Q1 2018-Q4 2018-Q3 2018-Q2 2018-Q1 2017-Q4 2017-Q3 2017-Q2 2017-Q1 2016-Q4 2016-Q3 2016-Q2 2016-Q1 2015-Q4 2015-Q3 2015-Q2 2015-Q1 2014-Q4 2014-Q3 2014-Q2 2014-Q1 2013-Q4 2013-Q3 2013-Q2 2013-Q1 2012-Q4 2012-Q3 2012-Q2 2012-Q1 2011-Q4 2011-Q3 2011-Q2 2011-Q1

Operating Cash Flow

- - -19.7 M - - - -2.22 M - - - -14.7 M - -52.1 M -38.8 M -26 M - -78.9 M -65.5 M -33.2 M - -69.8 M -45.9 M -24.6 M - -56.5 M -32.9 M -14.3 M - -43.9 M -31.3 M -16.4 M - -23.9 M -14.2 M -5.4 M - -14.7 M -9.97 M -5.17 M - -11.3 M -8.67 M -4.22 M - -11.8 M -9.34 M -5.04 M - -7.93 M -5.7 M -3.07 M - -5.1 M -3.04 M -2 M - -5.18 K -18 K -445 K

Depreciation & Amortization

2 M 2 M 1.9 M - 1.9 M 1.9 M 1.9 M - 1.9 M 1.9 M 1.9 M - 1.7 M 1.5 M 1.4 M - 1.2 M 1.1 M 1.1 M - 900 K 700 K 600 K - 818 K 806 K 805 K 211 K 847 K 846 K 830 K - 836 K 277 K 118 K - 117 K 116 K 118 K - 118 K 118 K 117 K - 54.2 K 48.6 K 48.3 K - 54.9 K 60.6 K 43.6 K - 48.9 K 46.1 K 45.7 K - 54.9 K 54.9 K 54.9 K

Accounts Payables

24 M 29.8 M 20.6 M 20.2 M 16 M 14.2 M 17.2 M 15.7 M 10.9 M 12.1 M 13 M 13.2 M 25.2 M 11.4 M 14.1 M 12.4 M 17.3 M 6.17 M 12.2 M 11.1 M 11.1 M 11.1 M 11.1 M 9.17 M 9.17 M 9.17 M 9.17 M 5.9 M 5.9 M 5.9 M 5.9 M 5.92 M 5.92 M 5.92 M 5.92 M 2.56 M 2.56 M 2.56 M 2.56 M 2.09 M 2.09 M 2.09 M 2.09 M 1.78 M 1.78 M 1.78 M 1.78 M 2.71 M 2.71 M 2.71 M 2.71 M 1.06 M 1.06 M 1.06 M 1.06 M 1.3 M 1.3 M 1.3 M 1.3 M

Accounts Receivables

138 M 110 M 99.4 M 50 M 50.1 M 30.1 M 49.6 M 27.4 M 31.3 M 36.7 M 26.5 M 15.5 M 20.9 M 18.9 M 25.6 M 28.6 M 20.4 M 23.5 M 15.4 M 13.2 M 13.2 M 13.2 M 13.2 M 3.47 M 3.47 M 3.47 M 3.47 M 1.39 M 1.39 M 1.39 M 1.39 M 3.88 M 3.88 M 3.88 M 3.88 M 1.02 M 1.02 M 1.02 M 1.02 M 924 K 924 K 924 K 924 K 384 K 384 K 384 K 384 K - - - 326 K 39.1 K 39.1 K 39.1 K 39.1 K - - - -

Total Inventories

197 M 191 M 172 M 170 M 172 M 180 M 178 M 173 M 163 M 162 M 164 M 163 M 163 M 146 M 139 M 125 M 114 M 99.7 M 94.1 M 81.5 M 81.5 M 81.5 M 81.5 M 53.1 M 53.1 M 53.1 M 53.1 M 18.6 M 18.6 M 18.6 M 18.6 M 12.6 M 12.6 M 12.6 M 12.6 M 5.02 M 5.02 M 5.02 M 5.02 M 3.45 M 3.45 M 3.45 M 3.45 M 1.71 M 1.71 M 1.71 M 1.71 M 1.67 M 1.67 M 1.67 M 1.67 M 1.27 M 1.27 M 1.27 M 1.27 M 1.15 M 1.15 M 1.15 M 1.15 M

All numbers in USD currency

Cash Flow Statement is one of the three key financial reports of the company ADMA Biologics, reflecting the actual cash inflows and outflows over a certain period. Unlike the income statement, which shows revenues and expenses on an accrual basis, the cash flow statement focuses on real cash flows — how much cash actually came into the company and how much was spent.

Main Sections of the Cash Flow Statement
  • Operating Activities
    This section reflects cash flows related to the company’s core operations: receipts from sales of goods and services, payments to suppliers, employee salaries, taxes, and other operating expenses. Positive cash flow from operating activities indicates the viability of the business and its ability to generate cash.
  • Investing Activities
    Shows cash movements related to the purchase and sale of long-term assets such as real estate, equipment, and investments in other companies. Negative cash flow here often indicates investments in growth, which can be a positive sign.
  • Financing Activities
    Reflects the inflow and outflow of cash related to raising and repaying capital: issuing shares, loans, dividend payments, and loan repayments. This section shows how the company finances its activities and distributes profits.

The cash flow statement is important for investors because it allows them to assess the company’s real liquidity, showing whether it has enough cash to cover current obligations and investments — this is critical for financial stability. Additionally, it helps analyze the quality of earnings, since profits reported in the income statement can be "paper" profits and may not reflect actual cash inflows; the cash flow statement reveals this difference. The presence of free cash is also crucial for evaluating the company’s ability to finance growth and pay dividends, which is important for investors. Attention should also be paid to prolonged negative cash flows from operating activities, as this may serve as a warning sign of potential problems with the core business.

Cash flow statements of other stocks in the Biotechnology sector

Issuer Price % 24h Market Cap Country
Assembly Biosciences Assembly Biosciences
ASMB
$ 28.46 3.45 % $ 319 M usaUSA
Ascendis Pharma A/S Ascendis Pharma A/S
ASND
$ 221.88 -0.87 % $ 5 B danmarkDanmark
MorphoSys AG MorphoSys AG
MOR
- 2.43 % $ 254 M germanyGermany
Axsome Therapeutics Axsome Therapeutics
AXSM
$ 156.92 -1.23 % $ 7.81 B usaUSA
Galera Therapeutics Galera Therapeutics
GRTX
- -32.59 % $ 7.61 M usaUSA
Pharming Group N.V. Pharming Group N.V.
PHAR
$ 15.36 -0.71 % $ 7.59 B niderlandNiderland
Autolus Therapeutics plc Autolus Therapeutics plc
AUTL
$ 1.37 -4.2 % $ 350 M britainBritain
Kamada Ltd. Kamada Ltd.
KMDA
$ 8.5 -1.39 % $ 260 M israelIsrael
I-Mab I-Mab
IMAB
- - $ 866 M chinaChina
Genfit SA Genfit SA
GNFT
- 2.54 % $ 160 B franceFrance
Benitec Biopharma Benitec Biopharma
BNTC
$ 10.98 -4.52 % $ 452 M usaUSA
Inventiva S.A. Inventiva S.A.
IVA
$ 5.78 -4.3 % $ 138 M franceFrance
Biophytis SA Biophytis SA
BPTS
- -13.47 % $ 169 M franceFrance
Compugen Ltd. Compugen Ltd.
CGEN
$ 2.09 -0.95 % $ 195 M israelIsrael
Tiziana Life Sciences PLC Tiziana Life Sciences PLC
TLSA
$ 1.21 -3.97 % $ 71.5 M britainBritain
ARCA biopharma ARCA biopharma
ABIO
- 1052.0 % $ 415 M usaUSA
Midatech Pharma plc Midatech Pharma plc
MTP
- -18.52 % $ 27.3 M britainBritain
Aeterna Zentaris Aeterna Zentaris
AEZS
- 5.93 % $ 314 M canadaCanada
Applied Genetic Technologies Corporation Applied Genetic Technologies Corporation
AGTC
- - $ 26.5 M usaUSA
PainReform Ltd. PainReform Ltd.
PRFX
$ 2.28 -0.44 % $ 1.03 M israelIsrael
Acorda Therapeutics Acorda Therapeutics
ACOR
- -24.86 % $ 820 K usaUSA
Acasti Pharma Acasti Pharma
ACST
- 4.01 % $ 150 M canadaCanada
Foghorn Therapeutics Foghorn Therapeutics
FHTX
$ 5.0 2.25 % $ 315 M usaUSA
Adverum Biotechnologies Adverum Biotechnologies
ADVM
- - $ 86.2 M usaUSA
Acer Therapeutics Acer Therapeutics
ACER
- 2.71 % $ 14 M usaUSA
Advaxis Advaxis
ADXS
- -9.65 % $ 45.9 M usaUSA
AbCellera Biologics AbCellera Biologics
ABCL
$ 3.4 -3.68 % $ 1.02 B canadaCanada
BioMarin Pharmaceutical BioMarin Pharmaceutical
BMRN
$ 54.13 -1.64 % $ 10.4 B usaUSA
Curis Curis
CRIS
$ 0.77 1.89 % $ 4.86 M usaUSA
Bellerophon Therapeutics Bellerophon Therapeutics
BLPH
- -74.18 % $ 955 K usaUSA
AgeX Therapeutics AgeX Therapeutics
AGE
- -10.17 % $ 12.2 K usaUSA
Coherus BioSciences Coherus BioSciences
CHRS
$ 1.52 -5.59 % $ 178 M usaUSA
Aeglea BioTherapeutics Aeglea BioTherapeutics
AGLE
- - $ 1.01 B usaUSA
CureVac N.V. CureVac N.V.
CVAC
- - $ 867 M germanyGermany
Burford Capital Limited Burford Capital Limited
BUR
$ 7.7 -5.87 % $ 1.29 B britainBritain
Akero Therapeutics Akero Therapeutics
AKRO
- - $ 3.67 B usaUSA
Cellectis S.A. Cellectis S.A.
CLLS
$ 3.34 -4.02 % $ 116 M franceFrance
Arbutus Biopharma Corporation Arbutus Biopharma Corporation
ABUS
$ 4.24 -2.97 % $ 704 M canadaCanada
Akouos Akouos
AKUS
- 0.23 % $ 488 M usaUSA
Albireo Pharma Albireo Pharma
ALBO
- -0.23 % $ 916 M usaUSA
AIkido Pharma AIkido Pharma
AIKI
- 1.93 % $ 17.4 M usaUSA
Cardiff Oncology Cardiff Oncology
CRDF
$ 1.8 -1.1 % $ 120 M usaUSA
Allakos Allakos
ALLK
- - $ 28.6 M usaUSA
Cabaletta Bio Cabaletta Bio
CABA
$ 2.94 -3.29 % $ 3.43 M usaUSA
Iterum Therapeutics Iterum Therapeutics
ITRM
$ 0.16 -5.45 % $ 3.15 M irlandaIrlanda
Brickell Biotech Brickell Biotech
BBI
- -5.38 % $ 6.06 M usaUSA
Allena Pharmaceuticals Allena Pharmaceuticals
ALNA
- 3.16 % $ 1.9 M usaUSA